Correction
1
Correction Schmieder R, Puehler F, Neuhaus R, Kissel M, Adjei AA, Miner JN, Mumberg D, Ziegelbauer K, and Scholz A (2013). Allosteric MEK1/2 inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models of hepatocellular carcinoma. Neoplasia 15, 1161–1171. The correct pagination is 1147–1157.
Transcript of Correction
CorrectionSchmieder R, Puehler F, Neuhaus R, Kissel M, Adjei AA, Miner JN, Mumberg D, Ziegelbauer K, and Scholz A (2013). Allosteric MEK1/2inhibitor refametinib (BAY 86-9766) in combination with sorafenib exhibits antitumor activity in preclinical murine and rat models ofhepatocellular carcinoma. Neoplasia 15, 1161–1171.
The correct pagination is 1147–1157.
